mTOR signaling is excessive activated in tumor NK cells from patients with liver cancer, but is inhibited in peripheral blood NK cells from patients with metastatic breast cancer, and such aberrant mTOR activity is a critical driver of NK cell dysfunction (36, 37). Here, MTOR is linked to liver cancer.